Challenges and Opportunities of Pharmacogenetics in Drug Development

• Weaver R , GrahamKS, BeattieIG, RileyRJ: Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.Drug Metab. Dispos.31, 955–966 (2003).
   PubMed Web of Science ®Google Scholar
• Kuwayama H , LukG, YoshidaS: Efficacy of a low-dose omeprazole-based triple-therapy regimen for Helicobacter pylori eradication independent of cytochrome P450 genotype: The Japanese MACH Study.Clin. Drug Invest.25, 293–305 (2005).
   Google Scholar
• Kim K , JohnsonJA, DerendorfH: Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.J. Clin. Pharmacol.44, 1083–1105 (2004).
   PubMed Web of Science ®Google Scholar
• Gibson N , JawaidA, MarchR: Novel technology and the development of pharmacogenetics within the pharmaceutical industry.Pharmacogenomics6, 339–356 (2005).
   PubMed Web of Science ®Google Scholar
• Marzolini C , TironaRG, KimRB: Pharmacogenomics of the OATP and OAT families.Pharmacogenomics5, 273–282 (2004).
   PubMed Web of Science ®Google Scholar
• Lee E , RyanS, BirminghamB et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharm. Ther.78, 330–341 (2005).
   PubMed Web of Science ®Google Scholar
• Mahgoub A , IdleJR, DringLG, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet2, 584–586 (1977).
   PubMed Web of Science ®Google Scholar
• Zineh I , GerhardT, AquilanteCL et al.: Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs.Pharmacogenomics J.4, 354–358 (2004).
   PubMed Web of Science ®Google Scholar
• Lesko LJ , WoodcockJ: Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.Nature Rev. Drug Discov.3, 763–769 (2004).
   PubMed Web of Science ®Google Scholar
• Innocenti F , UndeviaSD, IyerL et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol.22, 1382–1388 (2004).
   PubMed Web of Science ®Google Scholar
• Huang SM , GoodsaidF, RahmanA, Frueh F, Lesko L: Application of pharmacogenomics in clinical pharmacology. Toxicol. Mech. Methods16, 89–99 (2006).
   PubMed Web of Science ®Google Scholar
• Harries M , SmithI: The development and clinical use of trastuzumab (Herceptin).Endocr. Relat. Cancer9, 75–85 (2002).
   PubMed Web of Science ®Google Scholar
• US FDA and CMS in talks on coverage for pharmacogenomics tests. CLINICA World Medical Device and Diagnostic News. December 07, 2005.
   Google Scholar
• Johnson D : Gefitinib (Iressa) trials in non-small cell lung cancer.Lung Cancer41(Suppl. 1), S23–S28 (2003).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaR et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG , JannePA, LeeJC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Eberhard DA , JohnsonBE, AmlerLC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J. Clin. Oncol.23, 5900–5909 (2005).
   PubMed Web of Science ®Google Scholar
• Bell DW , LynchTJ, HaserlatSM et al.: Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol.23, 8081–8092 (2005).
   PubMed Web of Science ®Google Scholar
• Speake G , HollowayB, CostelloG: Recent developments related to the EGFR as a target for cancer chemotherapy.Curr. Opin. Pharmacol.5, 343–349 (2005).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F , HirschFR, RossiE et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J. Natl. Cancer Inst.97, 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch FR , Varella-GarciaM, BunnPA et al.: Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small cell lung cancer (aNSCLC) treated with gefitinib or placebo (ISEL trial). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, USA, Abstract A268 (2005).
   Google Scholar
• Holloway B , ThatcherN, ChangA et al.: Epidermal growth factor (EGFR), K-Ras and B-Raf mutation status and clinical outcome to gefitinib (IRESSA) in a Phase III placebo-controlled study (ISEL) in advanced non-small cell lung cancer (aNSCLC). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, USA, Abstract A269 (2005).
   Google Scholar
• Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279, 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M , JamesS, MeakinS et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ329, 15–19 (2004).
   PubMed Web of Science ®Google Scholar
• Mallal S , NolanD, WittC et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet359, 727–732 (2002).
   PubMed Web of Science ®Google Scholar
• Hetherington S , HughesAR, MostellerM et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet359, 1121–1122 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes DA , JavierV, WardCC et al.: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics14, 335–342 (2004)
   PubMedGoogle Scholar
• Bridgland-Taylor MH , HargreavesAC, EasterA et al.: Optimization and validation of a medium-throughput electrophysiology-based hERG assay using IonWorkstrade mark HT. J. Pharmacol. Toxicol. Methods. [Epub ahead of print] (2006).
   PubMedGoogle Scholar
• Royal S ociety: Personalised medicines: hopes and realities. Royal Society, London, UK (2005).
   Google Scholar
• Thomas DC , ClaytonDG: Betting odds and genetic associations.J. Natl. Cancer Inst.96, 421–423 (2004).
   PubMed Web of Science ®Google Scholar
• Lohmueller KE , PearceCL, PikeM, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nature Genet.33, 177–182 (2003).
   PubMed Web of Science ®Google Scholar
• McCarthy A , KerrM, AbadieE et al.: Report on the joint EFPIA, DIA and EMEA pharmacogenetics workshop: moving toward clinical application. Pharmacogenomics5, 731–739 (2004).
   PubMedGoogle Scholar
• Thomas SM : Society and ethics – the genetics of disease.Curr. Opin. Genet. Dev.14, 287–291 (2004).
   PubMed Web of Science ®Google Scholar
• March R , CheesemanK, DohertyM: Pharmacogenetics – legal, ethical and regulatory considerations.Pharmacogenomics2, 317–327 (2001).
   PubMedGoogle Scholar
• Knudsen LE : Global gene mining and the pharmaceutical industry.Toxicol. Appl. Pharmacol.207, 679–683 (2005).
   PubMedGoogle Scholar
• Anderson DC , Gomez-MancillaB, Spear BB et al.: Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Pharmacogenomics J.2, 284–292 (2002).
   PubMedGoogle Scholar
• Renegar G , WebsterCJ, StuerzebecherS et al.: Returning genetic research results to individuals: points-to-consider. Bioethics20, 24–36 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• PhRMA mission statement. www.phrma.org/whoweare/mission/
   Google Scholar
• CMR International Institute for Regulatory Science. www.cmr.org/institute/
   Google Scholar
• von Eschenbach AC: The future of protecting and promoting public health. www.fda.gov/fdac/departs/2006/106_word.html
   Google Scholar
• Temple R: Definition of biomarkers. www.fda.gov/cder/genomics/presentations_20051006/051007_10_Temple.pdf
   Google Scholar
• Parodi L, Pfizer Inc.: Optimizing irinotecan safety/efficacy profile with UGT1A1 genotypes. www.fda.gov/cder/genomics/presentations_20051006/051007_B3_Parodi.pdf
   Google Scholar
• Proceedings of the Clinical Pharmacology Subcommittee (CPSC) of the Advisory Committee for Pharmaceutical Science (ACPS) November 14, 2005. www.fda.gov/ohrms/dockets/ac/05/slides/2005–4194S1_Slide-Index.htm
   Google Scholar
• Announcement of the Collaborative Cardiovascular Drug Safety and Biomarker Research Program. www.fda.gov/oc/initiatives/criticalpath/biomarker.html
   Google Scholar
• Pirmohamed M (University of Liverpool): Variability in response to warfarin: a prospective analysis of pharmacogenetic and environmental factors. www.genres.org.uk/prp/projectsliverpool2.htm
   Google Scholar
• Genentech 2004 Annual Report. www.gene.com/gene/ir/financials/annual-reports/2004/financials/marketedproducts.jsp
   Google Scholar
• FDA draft concept paper on drug–diagnostic co-development. www.fda.gov/cder/genomics/pharmacoconceptfn.pdf
   Google Scholar
• Human Genome Project ethical, legal, and social issues. www.ornl.gov/sci/techresources/Human_Genome/elsi/elsi.shtml
   Google Scholar
• FDA (2005). Guidance for industry pharmacogenomic data submissions, FDA, Maryland, USA. www.fda.gov/cder/guidance/6400fnl.pdf
   Google Scholar
• Genomics and personalized medicine. www.fda.gov/fdac/features/2005/605_genomics.html
   Google Scholar
• Source: keyword search on “pharmacogenetics”. www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed
   Google Scholar
• The promise of pharmacogenomics. Available at: www.ncbi.nlm.nih.gov/About/primer/ pharm.html
   Google Scholar
• FDA fosters pharmacogenomics. www.bio-itworld.com/archive/061202/horizons_lesko.html
   Google Scholar
• Woodcock J: Pharmacogenomics: on the road to ‘personalized medicine‘. www.fda.gov/fdac/departs/2005/605_word.html
   Google Scholar